Theravance Biopharma shareholders held extraordinary general meeting on merger proposals

Theravance Biopharma held an extraordinary general meeting on Sept. 18, 2026 to vote on merger-related resolutions. The meeting approved a special resolution authorizing the merger agreement and related transaction documents, including the plan of merger. The resolution also authorized amendments to the company’s memorandum and articles, plus an increase in authorized share capital tied to the merger structure. A separate advisory resolution on merger-related executive compensation was approved. The votes authorized the transactions but did not confirm completion or closing of the merger. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-108980), on September 18, 2026, and is solely respon